Foreign media: British pharmaceutical giant GlaxoSmithKline (GSK) recently announced it will acquire the global rights to a cancer drug developed by Chengdu-based Chimagen Biosciences, with a potential payment of up to $750 million, highlighting growing international interest from global pharmaceutical companies in China's biotech innovation capabilities.
The drug is a T-cell engager (TCE) targeting multiple myeloma, which works by directing immune T cells to attack cancer cells. GSK stated that compared to existing TCE therapies, this drug shows potential in terms of tolerability and sustained efficacy, and is expected to enter Phase I clinical trials next year.
In recent years, Chinese innovative drug companies have accelerated their expansion into global markets through licensing collaborations. Data shows that the total value of overseas licensing deals for Chinese innovative drugs has reached $12 billion this year, representing a 36% year-on-year increase. Previously, AstraZeneca's licensing agreement with Stone Medicine Group for a weight-loss drug had a potential payment amount as high as $18.5 billion, further demonstrating global pharmaceutical companies' increasing attention to China's biomedical research achievements.
Original source: toutiao.com/article/1876503188718604/
Disclaimer: The views expressed in this article are solely those of the author.